Regulatable C-X-C chemokine receptor type 4 in iPSC-derived NK cells improves bone marrow chemotaxis and targeting resident tumor
Trends in Biotechnology · 2025-07 · 43 (7) · 1668-1689
DOI: 10.1016/j.tibtech.2025.02.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Biotechnology, 2025-07. Verfasst von Xiangjun He und 30 weiteren Autor:innen. Beteiligte Einrichtung: Qihan Bio Inc., Hangzhou, Zhejiang, China. Electronic address: xiangjun.he@qihanbio.com. Hauptthemen laut MEDLINE: Killer Cells, Natural, Receptors, CXCR4, Induced Pluripotent Stem Cells, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Tsinghua University, Science and Technology Department of Zhejiang Province.
Abstract (Originalsprache)
iPSC-derived natural killer cells (iNKs) have emerged as a promising cellular therapy, especially for the refractory or relapsed acute myeloid leukemia (R/R AML) patients, but limited research focused on the chemotaxis of iNKs. Here we demonstrate that C-X-C chemokine receptor type 4 (CXCR4) is significantly reduced in iNKs, resulting in impaired bone marrow (BM) infiltration, which cannot be rescued by constitutively expressed CXCR4 in iPSC due to CXCR4-induced differentiation failure. To address this, we developed a strategy to allow specific expression of CXCR4 during the iNK maturation stage without compromising the final iNK yield and function. The engineered iNKs exhibited enhanced BM infiltration, resulting in improved therapeutic effects in AML murine models. This, brought attention to iNK chemotaxis, provided a meaningful strategy by incorporating well-designed gene editing with stem cells for cell product development, and obtained improved effective NK cells for AML therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Qihan Bio Inc., Hangzhou, Zhejiang, China. Electronic address: xiangjun.he@qihanbio.com.
- Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Qihan Bio Inc., Hangzhou, Zhejiang, China.
- Institute of Immunology and Department of Rheumatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, China.
Förderung
- National Natural Science Foundation of China
- Tsinghua University
- Science and Technology Department of Zhejiang Province
Zitieren
APA
He, X., Wang, L., Zeng, W., Wang, Y., Chen, N., Yang, P., Ti, A., Zhang, Q., Shao, Y., Wang, M., Huang, Z., Zhang, X., Xu, M., Liang, L., Wang, X., Ding, X., Zhu, T., Zhang, P., Pan, Z., …, & Yang, L. (2025). Regulatable C-X-C chemokine receptor type 4 in iPSC-derived NK cells improves bone marrow chemotaxis and targeting resident tumor. Trends in Biotechnology, 43(7), 1668-1689. https://doi.org/10.1016/j.tibtech.2025.02.018
Vancouver
He X, Wang L, Zeng W, Wang Y, Chen N, Yang P, et al. Regulatable C-X-C chemokine receptor type 4 in iPSC-derived NK cells improves bone marrow chemotaxis and targeting resident tumor. Trends in Biotechnology. 2025;43(7):1668-1689. doi:10.1016/j.tibtech.2025.02.018
BibTeX
@article{He2025,
author = {He, Xiangjun and Wang, Linqin and Zeng, Wenxiu and Wang, Yiyun and Chen, Nian and Yang, Peng and Ti, Aijun and Zhang, Qi and Shao, Yuxuan and Wang, Mengyan and Huang, Zihan and Zhang, Xueyan and Xu, Mengqi and Liang, Lingmin and Wang, Xinye and Ding, Xiaohui and Zhu, Tingting and Zhang, Peng and Pan, Ziyi and Yang, Fei and Zhou, Yixuan and Mo, Guolong and Hu, Jiabiao and Yue, Yanan and Hu, Jiapan and Deng, Yujie and Ho, Tony and Church, George M and Hu, Yongxian and Huang, He and Yang, Luhan},
title = {Regulatable C-X-C chemokine receptor type 4 in iPSC-derived NK cells improves bone marrow chemotaxis and targeting resident tumor},
journal = {Trends in Biotechnology},
year = {2025},
volume = {43},
number = {7},
pages = {1668--1689},
doi = {10.1016/j.tibtech.2025.02.018}
}
EUVIMED